-
TDP43, OXPHOS, and EGFR-TKI Resistance in TNBC
2026-09-12
This 2026 study identifies TDP43 as a metabolic regulator of EGFR-TKI resistance in triple-negative breast cancer, linking its mitochondrial translocation to oxidative phosphorylation and breast cancer stem-cell enrichment. The work also positions atovaquone as a repurposing candidate that may restore EGFR-TKI sensitivity by suppressing the TDP43–OXPHOS axis, although further translational validation is required.
-
HSP90 Regulation of RNA Foci in DM1
2026-09-12
A small-molecule screen in myotonic dystrophy type 1 myoblasts identified HSP90 as a regulator of pathogenic DMPK mRNA and CUGexp RNA foci. The study further connects this effect to p-STAT3 in undifferentiated cells while showing that differentiation reverses the response, highlighting cell state as a critical experimental variable.
-
Rucaparib and the Splicing-Repair Frontier
2026-09-11
Rucaparib (AG-014699, PF-01367338) offers a precise pharmacologic lens for studying PARP1, persistent DNA damage, and radiosensitivity. By connecting established prostate cancer models with new evidence on SmD2 acetylation and BRCA1/FANC splicing in hepatocellular carcinoma, this article presents a translational framework for biomarker-led PARP inhibitor research.
-
Making CYP2C19 Metabolism More Human-Relevant
2026-09-11
A translational framework for using (S)-Mephenytoin as a mechanistically interpretable CYP2C19 substrate across recombinant enzyme assays and hiPSC-derived intestinal organoids, while preserving the boundaries between validated evidence and forward-looking workflow design.
-
Omega-3s, Glymphatic Clearance, and Sevoflurane
2026-09-10
This study links repeated neonatal sevoflurane exposure to impaired glymphatic transport, phosphorylated tau accumulation, mitochondrial dysfunction, and later cognitive and fine motor abnormalities. Its central innovation is the identification of omega-3 polyunsaturated fatty acids as a maternal dietary intervention that preserves AQP4 polarization through PDGF-B/PDGFRβ signaling and improves phosphorylated tau clearance.
-
Berberine Hydrochloride: From AMPK to the Gut-Bone Axis
2026-09-10
Berberine hydrochloride is moving beyond a conventional metabolic research reagent. New evidence connects its microbiome-modulating activity with butyrate, GPR41, intestinal tuft cells, barrier integrity, and osteoimmune balance. This thought-leadership article translates those findings into a practical framework for metabolic, microbiome, bone, and translational research while distinguishing mechanistic promise from clinical readiness.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-09-09
A 2025 study found that selected naturally occurring angiotensin peptides enhance SARS-CoV-2 spike binding to AXL, ACE2, and NRP1, with peptide length and Tyr4 modification governing activity. The results connect renin-angiotensin system peptide processing with viral receptor biology, while remaining preliminary because the work used binding assays rather than infection or in vivo disease models.
-
GI 254023X: ADAM10 Inhibitor Workflows
2026-09-09
GI 254023X enables selective interrogation of ADAM10 sheddase activity in Jurkat signaling and endothelial barrier models. This workflow-focused guide connects target engagement with Notch1, VE-cadherin, toxin-challenge, and functional readouts while emphasizing exposure control and assay troubleshooting.
-
CFDA SE Cell Tracer Kit: Practical Guide
2026-09-08
The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell lineage tracing, cell proliferation studies, and related in vitro or in vivo tracking workflows. It is best suited to multi-day monitoring with covalent dye retention, but it is not the preferred choice for reversible, short-term, or real-time labeling applications.
-
Palbociclib Nanocrystal Gel for Local Breast Cancer Therapy
2026-09-08
The reference study combines palbociclib nanocrystals with a thermoresponsive poloxamer gel to address poor solubility and improve localized drug exposure in breast cancer models. Its findings connect nanoscale formulation, sustained intratumoral release, cellular uptake, oxidative stress, migration, and apoptosis-related responses, while also identifying important questions for translational validation.
-
AMG 487: State-Aware CXCR3 Antagonism
2026-09-07
AMG 487 is a potent CXCR3 antagonist for dissecting chemokine-driven migration, calcium signaling, and macrophage polarization. This article explains how to use it as a state-aware pharmacological perturbation rather than a generic pathway inhibitor, with assay design grounded in the 2024 LAMP1–CXCL10–CXCR3 study.
-
Metal-Ion-Chelating L-Phe Nanostructures and ICB
2026-09-05
A Nature Nanotechnology study shows that metal-ion-chelating L-phenylalanine nanostructures can reprogram dendritic-cell electrophysiology and remodel immunosuppressive breast and colorectal tumour microenvironments. Short-term starvation enhanced nanostructure uptake and helped connect ion-channel activity, inflammasome signaling, dendritic-cell maturation, and improved immune checkpoint blockade responses.
-
Disodium bicinchoninate for Cardiac Assays
2026-09-05
Disodium bicinchoninate provides a water-compatible route for BCA-style biochemical measurements that support high-glucose cardiomyocyte, fibroblast, and BMSC studies. This guide connects reagent handling with the cGMP/PKG findings of a cardiac fibrosis study, emphasizing fresh aqueous preparation, matrix controls, and orthogonal validation.
-
Cyclophosphamide: Mechanism and Research Uses
2026-09-04
Cyclophosphamide is an alkylating chemotherapeutic agent and hepatic prodrug that generates DNA-reactive metabolites. Its research value spans apoptosis induction in cancer cells, lymphocyte suppression, and bone marrow transplantation conditioning, but model-specific activation and toxicity limits interpretation.
-
Primary Antibody Dilution Buffer for PCNSL Assays
2026-09-04
Translate single-cell evidence on SLC2A5-driven fructose metabolism into reproducible IHC, ICC, and ISH validation workflows. Learn how a specialized antibody dilution buffer can support tissue penetration, lower nonspecific signal, and improve assay troubleshooting without overstating discovery-stage evidence.